IP Library Granted Patent US 9,795,684
Granted Patent B2
US 9,795,684 · App. 14/961,096 · Granted Oct 24, 2017

Interfering RNA delivery system and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,795,684
App. No.
14/961,096
Granted
Oct 24, 2017
Kind
B2
Abstract

The invention provides a delivery system comprising a cell penetrating peptide, a polyarginine peptide, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.

Claims (17)

1. An interfering RNA delivery system comprising an interfering RNA molecule linked to a cell penetrating peptide-polyarginine peptide (CPP-Arg peptide), wherein the CPP comprises the amino acid of SEQ ID NO:2, and the Arg comprises SEQ ID NO:1.

2. The delivery system of claim 1 , wherein the CPP-Arg peptide further comprises an HA2 peptide.

3. The delivery system of claim 1 , wherein the interfering RNA molecule is linked to the CPP-Arg peptide via a covalent bond.

4. The delivery system of claim 1 , further comprising a pharmaceutically acceptable carrier.

5. The delivery system of claim 1 , wherein the interfering RNA molecule is an siRNA, miRNA, or shRNA.

6. The delivery system of claim 5 , wherein the interfering RNA molecule is an siRNA.

7. The delivery system of claim 1 , wherein the CPP comprises at least one D-amino acid.

8. A method of inhibiting expression of a gene in vivo comprising administering to a subject the interfering RNA delivery system of claim 1 , wherein the interfering RNA molecule attenuates expression of the gene.

9. A method of delivering an interfering RNA molecule into a cell, comprising

administering the interfering RNA delivery system of claim 1 to the cell under conditions suitable for the system to enter the cell.

10. The method of claim 9 , wherein release of the system from the endosome inside the cell is enhanced in the presence of an HA2 peptide.

11. The method of claim 9 , wherein an HA2 peptide is introduced into the cell by administration of a CPP-HA2 peptide.

12. The method of claim 9 , wherein the CPP-Arg peptide further comprises an HA2 peptide.

13. The method of claim 9 , wherein the interfering RNA molecule is linked to the CPP-Arg peptide via a covalent bond.

14. The method of claim 9 , wherein the interfering RNA molecule is a siRNA, miRNA, or shRNA.

15. The method of claim 14 , wherein the interfering RNA molecule is an siRNA.

16. The method of claim 9 , wherein the CPP comprises at least one D-amino acid.

Assignments (4)
SECURITY INTEREST Recorded Aug 7, 2024
From: ARROWHEAD PHARMACEUTICALS, INC.
To: SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT
Reel/Frame 068510/0363 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2017
From: ALCON RESEARCH, LTD.
To: ARROWHEAD RESEARCH CORPORATION
Reel/Frame 043740/0549 →
CHANGE OF NAME Recorded Sep 29, 2017
From: ARROWHEAD RESEARCH CORPORATION
To: ARROWHEAD PHARMACEUTICALS, INC.
Reel/Frame 044069/0458 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2016
From: CHATTERTON, JON E.
To: ALCON RESEARCH, LTD.
Reel/Frame 040193/0885 →